Literature DB >> 6968260

Human lymphocyte markers defined by antibodies derived from somatic cell hybrids. II. A hybridoma secreting antibody against an antigen expressed by human B and null lymphocytes.

I G Beckman, J Bradley, D A Brooks, A Kupa, P J McNamara, M E Thomas, H Zola.   

Abstract

A hybridoma (FMC4) has been derived which secretes antibody showing selective reaction with human B lymphocytes, monocytes and some null lymphocytes. Few, if any, T lymphocytes in normal blood are stained, although stimulation of lymphocytes with PHA leads to an increase in the proportion of cells reacting with the hybridoma antibody. The antibody reacts with B and null lymphoblastoid cell lines but not with T cell lines. B chronic lymphocytic leukaemia (CLL) cells but not T-CLLs are stained and null-type acute lymphoblastic leukaemia (ALL) cells but not T-type ALL also react. Normal blood myeloid cells do not react with FMC4 supernatant whilst some myeloid leukaemias do. The expression of the antigen reacting with FMC4 supernatant suggests that FMC4 may secrete an antibody against the human equivalent of the Ia antigen.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6968260      PMCID: PMC1538949     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Study of human T and B lymphocytes with heterologous antisera. I Preparation, specificity and properties of antisera.

Authors:  J Brochier; Y A Abou-Hamed; J P Gueho; J P Revillard
Journal:  Immunology       Date:  1976-11       Impact factor: 7.397

2.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

3.  Separation of T and B lymphocytes by nylon wool columns: evaluation of efficacy by functional assays in vivo.

Authors:  D Trizio; G Cudkowicz
Journal:  J Immunol       Date:  1974-10       Impact factor: 5.422

4.  Cell surface markers for human T and B lymphocytes.

Authors:  G Brown; M F Greaves
Journal:  Eur J Immunol       Date:  1974-04       Impact factor: 5.532

5.  Heterologous specific antiserum for identification of human T lymphocytes.

Authors:  J L Touraine; F Touraine; D F Kiszkiss; Y S Choi; R A Good
Journal:  Clin Exp Immunol       Date:  1974-04       Impact factor: 4.330

Review 6.  Human Ia-type alloantigens: methods of detection, aspects of chemistry and biology, markers for disease states.

Authors:  P Wernet
Journal:  Transplant Rev       Date:  1976

7.  Distribution of Ia-like molecules on the surface of normal and leukemic human cells.

Authors:  S F Schlossman; L Chess; R E Humphreys; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1976-04       Impact factor: 11.205

8.  Evidence for origin of certain childhood acute lymphoblastic leukemias and lymphomas in thymus-derived lymphocytes.

Authors:  J Kersey; M Nesbit; H Hallgren; A Sabad; E Yunis; K Gajl-Peczalska
Journal:  Cancer       Date:  1975-10       Impact factor: 6.860

9.  The occurrence of the HL-B alloantigens on the cells of unclassified acute lymphoblastic leukemias.

Authors:  S M Fu; R J Winchester; H G Kunkel
Journal:  J Exp Med       Date:  1975-11-01       Impact factor: 14.307

10.  A new I subregion (I-J) marked by a locus (Ia-4) controlling surface determinants on suppressor T lymphocytes.

Authors:  D B Murphy; L A Herzenberg; K Okumura; L A Herzenberg; H O McDevitt
Journal:  J Exp Med       Date:  1976-09-01       Impact factor: 14.307

View more
  11 in total

1.  Biphenotypic leukaemia: a case of mixed T lymphoblastic and myeloblastic leukaemia.

Authors:  M A Morgan; C S Scott; J Tavares de Castro; H J Limbert; N Polli; D Catovsky; R D Pyrah; B E Roberts
Journal:  J Clin Pathol       Date:  1985-05       Impact factor: 3.411

2.  Intracytoplasmic inclusions in B prolymphocytic leukaemia: ultrastructural, cytochemical, and immunological studies.

Authors:  D S Robinson; J V Melo; C Andrews; S A Schey; D Catovsky
Journal:  J Clin Pathol       Date:  1985-08       Impact factor: 3.411

3.  Differential expression of HLA class II antigens on human fetal and adult lymphocytes and macrophages.

Authors:  J A Edwards; D B Jones; P R Evans; J L Smith
Journal:  Immunology       Date:  1985-07       Impact factor: 7.397

4.  The fine structure of normal lymphocyte subpopulations--a study with monoclonal antibodies and the immunogold technique.

Authors:  E Matutes; D Catovsky
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

5.  Diurnal variation of lymphocyte subsets identified by monoclonal antibodies.

Authors:  J V Bertouch; P J Roberts-Thomson; J Bradley
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-09

6.  Immune aspects of intestinal metaplasia of the stomach: an immunohistochemical study.

Authors:  Y Tsutsumi; H Nagura; K Watanabe
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

7.  An investigation of the action of disease modifying antirheumatic drugs on the rheumatoid synovial membrane: reduction in T lymphocyte subpopulations and HLA-DP and DQ antigen expression after gold or penicillamine therapy.

Authors:  M T Walters; J L Smith; K Moore; P R Evans; M I Cawley
Journal:  Ann Rheum Dis       Date:  1987-01       Impact factor: 19.103

8.  Comparison of serum and synovial fluid concentrations of beta 2-microglobulin and C reactive protein in relation to clinical disease activity and synovial inflammation in rheumatoid arthritis.

Authors:  M T Walters; F K Stevenson; R Goswami; J L Smith; M I Cawley
Journal:  Ann Rheum Dis       Date:  1989-11       Impact factor: 19.103

9.  Varying expression of major histocompatibility complex antigens on human renal endothelium and epithelium.

Authors:  P R Evans; L P Trickett; J L Smith; A G MacIver; D Tate; M Slapak
Journal:  Br J Exp Pathol       Date:  1985-02

10.  T-cell growth factor production by adult, but not childhood. Acute lymphoblastic leukaemic cells.

Authors:  R Seshadri; C Matthews; H Moore; H Zola
Journal:  Blut       Date:  1984-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.